^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ITGB2 underexpression

    i
    Other names: ITGB2, Integrin Subunit Beta 2, LFA-1, MAC-1, CD18, MFI7, Integrin, Beta 2 (Complement Component 3 Receptor 3 And 4 Subunit), Complement Component 3 Receptor 3 And 4 Subunit, Integrin Beta-2, Integrin, Beta 2 (Antigen CD18 (P95), Lymphocyte Function-Associated Antigen 1; Macrophage Antigen 1 (Mac-1) Beta Subunit), Cell Surface Adhesion Glycoprotein (LFA-1/CR3/P150,959 Beta Subunit Precursor), Cell Surface Adhesion Glycoproteins LFA-1/CR3/P150,95 Subunit Beta, Leukocyte-Associated Antigens CD18/11A, CD18/11B, CD18/11C, Leukocyte Cell Adhesion Molecule CD18, Complement Receptor C3 Beta-Subunit, Complement Receptor C3 Subunit Beta, Integrin Beta Chain, Beta 2, Truncated Integrin Beta-2, CD18 Antigen, LCAMB, MF17, LAD
    Entrez ID:
    3689
    over3years
    The Profile and Clinical Significance of ITGB2 Expression in Non-Small-Cell Lung Cancer. (PubMed, J Clin Med)
    Mechanistically, we demonstrated that ITGB2 suppressed the expression of N-cadherin, Vimentin, Slug, Snail, and Twist, while it promoted E-cadherin expression, according to gain-of-function studies. In conclusion, ITGB2 can inhibit the proliferation and migration of NSCLC cells, leading to a poor prognosis, via epithelial-mesenchymal transition (EMT) signaling.
    Journal
    |
    CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • ITGB2 (Integrin Subunit Beta 2) • SNAI2 (Snail Family Transcriptional Repressor 2)
    |
    CDH1 expression • VIM expression • ITGB2 underexpression